[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Dharmais National Cancer Center Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":87},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100610921","lymphovenous-bypass-procedure-for-secondary-prevention-of-lymphedema-in-breast-cancer-100610921",false,"NCT07233863","Lymphovenous Bypass Procedure for Secondary Prevention of Lymphedema in Breast Cancer","Effectiveness of Lymphovenous Bypass Procedure for Secondary Prevention of Lymphedema in Breast Cancer","Inclusion Criteria:\n\n* Breast cancer patients aged ≥ 18 years with an ECOG score \\> 1\n* Breast cancer patients with post-axillary lymph node dissection diagnosed with stage 0 and I lymphedema.\n* Those who have never undergone lymphedema physiotherapy.\n\nExclusion Criteria:\n\n* Patients with dermal backflow before axillary lymph node dissection (ALND).\n* Patients with breast cancer lymphedema who are unable to undergo a 24-month follow-up at Dharmais Cancer Hospital.\n* Patients with iodine allergy, severe asthma, decreased kidney function, pregnancy, or breastfeeding.","ALL","18 Years",{"count":19,"type":20},136,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to evaluate the effectiveness of the Lymphovenous Bypass (LVB) procedure compared to physiotherapy alone as secondary prevention of lymphedema in breast cancer patients undergoing axillary lymph node dissection.",[26],"Lymphedema Arm",[28,29],"Breast Cancer","Lymphedema","RECRUITING","2025-11-14",{"date":33,"type":34},"2025-11-18","ACTUAL",{"date":36,"type":34},"2024-03-18",{"date":38,"type":20},"2028-03-21",{"name":40,"class":41},"Dharmais National Cancer Center Hospital","OTHER_GOV",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":68,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":5},"100592462","effect-of-dexmedetomidine-on-microsurgery-reconstruction-in-cancer-patient-100592462","NCT06993740","Effect of Dexmedetomidine on Microsurgery Reconstruction in Cancer Patient","The Effect of Dexmedetomidine Administration on the Success of Reconstructive Microsurgery in Cancer Patients: A Study of Glycocalyx Integrity, Inflammatory Response, Thrombosis, Angiogenesis, Oxidative Stress, and Tissue Microcirculation","DEXFLAP","Inclusion Criteria:\n\n1. Adult patients (aged 18-65 years) diagnosed with cancer who are scheduled to undergo microsurgical flap reconstruction.\n2. Patients within the age range of 18 to 65 years at the time of enrollment.\n3. Patients who provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Patients with a history of uncontrolled diabetes mellitus.\n2. Patients diagnosed with chronic kidney disease.\n3. Patients with known liver failure.\n4. Patients receiving corticosteroid therapy prior to surgery.\n5. Patients with uncontrolled hypertension.\n6. Patients with a history of chemotherapy or radiotherapy prior to surgery.\n7. Patients diagnosed with preoperative sepsis.\n8. Patients requiring perioperative vasopressor support.\n9. Patients with a history of prior surgery in the same operative field.\n10. Patients who decline to participate in the study.","65 Years",{"count":53,"type":20},60,[23],"This double-blinded randomized controlled trial aims to investigate the effect of intraoperative dexmedetomidine administration on early flap viability and microvascular integrity in cancer patients undergoing elective microvascular reconstructive surgery. The primary outcome is clinical flap viability within 48 hours postoperatively, assessed using a standardized scoring system based on flap color, temperature, capillary refill time, and tissue turgor. Secondary outcomes include the evaluation of biomarkers related to endothelial glycocalyx degradation (syndecan-1), oxidative stress (SOD-1), inflammation (IL-6, IL-10), thrombosis (PAI-1), and angiogenesis (VEGF), as well as microcirculatory assessment using Sidestream Dark Field (SDF) imaging. The study is designed to determine whether dexmedetomidine improves early surgical outcomes by modulating pathophysiological processes involved in microvascular flap success.",[57,58,59,60,61,62,63,64,65,66,67],"Flap Monitoring","Inflammation","Thrombosis","Oxidative Stress","Glycocalyx","Anesthesia","Surgery","Flap Ischemia","Flap Necrosis","Flap Failure Risk Factors","Microsurgery",[69,70,71,72,73,74,75,76,77,78],"SOD-1","IL-6","IL-10","VEGF","Syndecan-1","Dexmedetomidine","SDF","PAI-1","Flap Failure","Flap Salvage","2025-06-11",{"date":81,"type":34},"2025-06-15",{"date":83,"type":34},"2025-06-10",{"date":85,"type":20},"2026-08-22",{"name":40,"class":41},""]